302 recruiting, 298 completed, 154 terminated, 143 active not recruiting. 604 Phase 2, 462 Phase 1, 100 Phase 3, 72 Not applicable, 25 Early Phase 1.
Follow Triple Negative Breast Neoplasms: new trials by email Literature Review of Triple Negative Breast Neoplasms trials Research Report on Triple Negative Breast Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | The University of The West Indies | 750 | 2027-06-01 | 2026-09-22 |
| Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) [18F]FMISO-PET with contrast-enhanced MRI - Triple Negative Breast Cancer | Early Phase 1 | Recruiting | University of Alabama at Birmingham | 20 | 2027-06-01 | 2026-08-17 |
| TROPION Breast Respond in 1L TNBC Dato-DXd - Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer | Not yet recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 400 | 2027-03-01 | 2026-10-09 | |
| A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes | Phase 2 | Recruiting | Medical University of South Carolina | 55 | 2027-01-01 | 2026-10-15 |
| Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer. BLEX 404 Oral Liquid - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | BioLite, Inc. | 44 | 2027-01-01 | 2026-04-13 |
| Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer Cromolyn, TQB2102, and Panpulimab - Triple -Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 46 | 2027-01-01 | 2026-09-25 |
| A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer Enter a brief, descriptive name for the intervention. Use a non-proprietary (generic) name, if available. SYS6043, Investigator's Choice of Chemotherapy (paclitaxel，nab paclitaxel，capecitabine，eribulin，carboplatin） - Triple Negative Breast Cancer | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 550 | 2026-11-30 | 2026-10-19 |
| Diet-drive Gut Microbiome and Outcome in Patients With Early-stage Triple-negative Breast Cancer Undergoing Neoadjuvant Chemotherapy and Immunotherapy. Triple Negative Breast Cancer (TNBC), Early Setting | Not yet recruiting | Barts & The London NHS Trust | 300 | 2026-11-13 | 2026-04-27 | |
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-11-05 | 2026-05-28 |
| Performance of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early Triple-Negative Breast Cancer Non interventional study - Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 100 | 2026-11-01 | 2026-07-07 | |
| Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer Pembrolizumab - Early Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 84 | 2026-11-01 | 2026-10-05 |
| A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 60 | 2026-11-01 | 2026-10-16 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | CoRegen, Inc. | 67 | 2026-11-01 | 2026-10-02 |
| A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. LNTH-2403 - Imaging, Colorectal Cancer | Phase 1 | Not yet recruiting | Radiopharm Theranostics, Ltd | 16 | 2026-10-30 | 2026-08-12 |
| Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer Fasten Onco, Standard Neoadjuvant Treatment - Triple-Negative Breast Cancer (TNBC) | Not applicable | Not yet recruiting | FASTEN | 144 | 2026-10-30 | 2026-10-21 |
| Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases Arm 1 - Breast Cancer, Breast Carcinoma | Recruiting | National Cancer Institute (NCI) | 139 | 2026-10-29 | 2026-10-26 | |
| A Clinical Study to Evaluate the Efficacy and Safety of JS212 Monotherapy or Combination Therapy in Recurrent or Metastatic Triple-negative Breast Cancer(TNBC) JS212 in combination with JS207, JS212 monotherapy, JS212 in combination with JS001 - Triple-negative Breast Cancer | Phase 2 | Not yet recruiting | Shanghai Junshi Bioscience Co., Ltd. | 184 | 2026-10-15 | 2026-10-15 |
| Pre-Treatment Breast DCE-MRI AI Model to Predict Neoadjuvant Chemotherapy Benefit in Locally Advanced Triple-Negative Breast Cancer Pre-treatment DCE-MRI-based AI model - Breast Neoplasm Female, Triple -Negative Breast Cancer | Recruiting | Fujian Cancer Hospital | 120 | 2026-10-08 | 2026-10-19 | |
| Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer Biopsy Procedure, Biospecimen Collection, Echocardiography Test - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Recruiting | National Cancer Institute (NCI) | 36 | 2026-10-06 | 2026-10-16 |
Showing 20 of 1200. Sign in to see all of them.
Breast Neoplasms (469) · Carcinoma, Non-Small-Cell Lung (197) · Ovarian Neoplasms (135) · Squamous Cell Carcinoma of Head and Neck (102) · Neoplasm Metastasis (93) · Colorectal Neoplasms (91) · Melanoma (90) · Carcinoma, Renal Cell (83) · Endometrial Neoplasms (76) · Neoplasms (74) · Stomach Neoplasms (74) · Uterine Cervical Neoplasms (69) · Pancreatic Neoplasms (58) · Small Cell Lung Carcinoma (58)
Skin and Connective Tissue Diseases (1200) · Skin Diseases (1199) · Breast Diseases (1197) · Neoplasms by Site (1197) · Neoplasms (1126) · Breast Neoplasms (731) · Neoplasms by Histologic Type (251) · Urogenital Diseases (235) · Urogenital Neoplasms (232) · Female Urogenital Diseases (230) · Female Urogenital Diseases and Pregnancy Complications (230) · Respiratory Tract Neoplasms (230) · Respiratory Tract Diseases (229) · Thoracic Neoplasms (229) · Lung Diseases (228)
pembrolizumab (172) · Carboplatin (151) · Paclitaxel (129) · Cyclophosphamide (96) · 130-nm albumin-bound paclitaxel (68) · Capecitabine (67) · Gemcitabine (54) · Doxorubicin (53) · Albumin-Bound Paclitaxel (45) · Taxes (42) · Cisplatin (41) · atezolizumab (41) · sacituzumab govitecan (35) · Nivolumab (34) · Epirubicin (33)
Fudan University (63) · National Cancer Institute (NCI) (45) · M.D. Anderson Cancer Center (28) · Novartis Pharmaceuticals (21) · AstraZeneca (14) · Merck Sharp & Dohme LLC (14) · City of Hope Medical Center (11) · Gilead Sciences (11) · Pfizer (11) · AbbVie (10) · Hoffmann-La Roche (10) · Mayo Clinic (10) · Memorial Sloan Kettering Cancer Center (10) · Sun Yat-sen University (10) · Chinese Academy of Medical Sciences (9)
United States (639) · China (243) · Spain (133) · France (123) · Canada (95) · United Kingdom (94) · Australia (93) · Italy (93) · South Korea (72) · Belgium (65) · Germany (62) · Japan (60) · Taiwan (52) · Israel (36) · Poland (35)
Priyanka Sharma, MD (6) · Clinton Yam (5) · Kari Wisinski, MD (5) · David Page, MD (4)
PMID 32450725, PMID 32101663, PMID 24529560, PMID 25092775, PMID 30345906, PMID 32379297, PMID 32966830, PMID 19299237, PMID 25349301, PMID 27872127, PMID 28564564, PMID 29501363, PMID 33278935, PMID 34037241, PMID 34173924, PMID 35042534, PMID 35728046, PMID 35857659, PMID 38979716, PMID 39302614, PMID 39558017, PMID 40443562, PMID 16011702, PMID 16077072, PMID 17135638, PMID 17438091, PMID 17641361, PMID 17785706, PMID 17991697, PMID 18258986, PMID 19097774, PMID 19487376, PMID 19647220, PMID 19917869, PMID 20157582, PMID 20304629, PMID 20404251, PMID 20556505, PMID 20586616, PMID 20872150, PMID 21208101, PMID 21304525, PMID 21383283, PMID 21437909, PMID 21483002, PMID 21633166, PMID 21671016, PMID 21708823, PMID 21796368, PMID 21818123
2023 (25), 2016 (23), 2017 (16), 2019 (16), 2018 (15), 2014 (11), 2025 (8), UM1CA186709 (8), 2015 (5), P30CA016672 (5), P30CA068485 (5), P30CA138292 (5), P30CA033572 (4), UM1CA186689 (4), UM1CA186704 (4)